DHR vs LAB
DHR: Danaher is a diversified conglomerate providing scientific instruments, diagnostics, and industrial solutions across life sciences, environmental monitoring, product identification, and healthcare globally. LAB: Standard BioTools provides advanced life science analytical platforms and high-parameter imaging technologies to power discovery in single-cell and spatial biology.
Side-by-side fundamentals
| Metric | DHR | LAB | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $179.14 | $0.82 | |
| Market cap as of 2026-07-23 | $125.9B | $346M | |
| P/E as of 2026-07-23 | 34.12 | 4.43 | LAB lower |
| PEG as of 2026-07-23 | 3.97 | n/a | |
| Net margin as of 2026-07-23 | +14.9% | +90.7% | LAB higher |
| Gross margin as of 2026-07-23 | +59.0% | +49.6% | DHR higher |
| Operating margin as of 2026-07-23 | +19.2% | -111.0% | DHR higher |
| ROE as of 2026-07-23 | +7.1% | +17.3% | LAB higher |
| ROA as of 2026-07-23 | +4.5% | +13.6% | LAB higher |
| Debt / equity as of 2026-07-23 | 0.35 | 0.00 | LAB lower |
| Revenue growth (YoY) as of 2026-07-23 | +4.0% | -49.2% | DHR higher |
| Revenue CAGR (3y) SEC XBRL | -2.7% | -4.5% | DHR higher |
| Dividend yield as of 2026-07-23 | +0.9% | n/a | |
| Beta as of 2026-07-23 | 0.78 | 1.45 | |
| 1-year return as of 2026-07-22 close | -5.7% | -39.8% | DHR higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.